GAS2 is reportedly involved in the disease transformation of CML 52 and exhibits an opposite effect on the inhibition or emergency granulopoiesis termination roles of ICSBP for leukaemia.53, 54. This evidence concerns the gene GAS2 and chronic myelogenous leukemia, BCR-ABL1 positive.